SLU-PP-332

SLU-PP-332 acts as a selective agonist of estrogen-related receptors (ERRα, ERRβ, ERRγ), which are nuclear transcription factors regulating metabolic gene expression.

• ERR activation: Binds to the ligand-binding domains of ERRs, inducing a conformational change that recruits transcriptional coactivators.
• Induction of metabolic genes: Increases transcription of genes such as PGC-1α, PPARδ, and CPT1b, involved in mitochondrial biogenesis, fatty acid oxidation, and energy metabolism.
• Increased energy expenditure: Promotes fat utilization as an energy source, enhancing oxygen consumption and ATP production in mitochondria.
• Improved mitochondrial function: Stimulates the formation of new mitochondria and enhances the efficiency of existing ones.

• Obesity and weight loss: Increases energy expenditure and fat oxidation, facilitating fat mass reduction.
• Type 2 diabetes: Improves insulin sensitivity and glucose metabolism.
• Exercise endurance: Enhances aerobic capacity and muscle endurance in animal models.
• Metabolic disorders: Potential therapeutic in conditions like hepatic steatosis and metabolic syndrome.
• Aging and longevity: By improving mitochondrial function, it may delay age-related decline.

Reported effects in preclinical studies include increased energy expenditure, fat loss, improved exercise endurance, enhanced mitochondrial biogenesis, and greater fatty acid oxidation. Improvements in insulin sensitivity and reduction of hepatic steatosis have also been observed. No significant estrogenic effects have been reported.

SLU-PP-332 is a research compound not approved for human use. No long-term safety data or adverse effect profiles in humans are available. In animal studies, no severe toxicities have been reported, but caution is warranted. Potential theoretical adverse effects include unwanted metabolic alterations, drug interactions, and unknown effects on hormonal signaling. It should not be used by pregnant or lactating women, or by individuals with liver or kidney disease without medical supervision.

SLU-PP-332 is not approved by any regulatory agency (FDA, EMA, etc.) for clinical use in humans. It is exclusively in preclinical research phase and is not legally marketed as a drug.

No established doses for humans. In mouse studies, doses of 5-10 mg/kg/day have been used via intraperitoneal or oral routes. Not recommended for human use without clinical trials.

Store lyophilized powder at -20°C, protected from light and moisture. Once reconstituted, keep at 4°C and use within 1-2 weeks. Avoid freeze-thaw cycles.